End-Organ Damage Leads to Spike in Economic Costs of Sickle Cell Disease

September 15th 2020, 5:30pm


Sickle cell disease is a costly disease for patients, but when those patients suffer from end-organ damage, the costs jump significantly.

Study Finds Limits to sCR Compared With MRD in Tracking MM Response

September 11th 2020, 11:30am


A new study suggests stringent complete response is less meaningful than minimal residual disease status when evaluating patients with multiple myeloma.

Education Level Linked to Outcomes in Patients With MM

September 9th 2020, 4:00pm


New data suggests a patient’s education level can be an important factor in the disease outcomes of patients with multiple myeloma.

Combination Therapy Benefits High-Risk Patients With MM, Study Says

September 3rd 2020, 5:00pm


A new analysis found patients with high-cytogenetic-risk multiple myeloma benefitted from adding daratumumab to their therapy.

Plasma Exchange Therapy MM Use, Cost Rose During Past 25 Years

August 31st 2020, 7:30pm


A new analysis finds therapeutic plasma exchange has become more costly, and more common among patients with multiple myeloma.

MRD an Exciting Advance, but Not Ready for MM Care Yet, Review Says

August 26th 2020, 3:30pm


A new opinion article suggests minimal residual disease (MRD) is not yet ready for “prime time” in the clinic, even though it’s already making a major impact on clinical trials.

FDA Actions Include Third CAR T-cell Therapy

August 17th 2020, 9:45am


Evidence-Based Oncology regulatory updates for August 2020 feature coverage of Kite Pharma's new CAR T-cell therapy and selinexor in DLBCL.

Review: MM Outcomes Greatly Improving, but New Agents Still Needed

August 16th 2020, 1:00pm


Investigators have made tremendous strides improving patient care in multiple myeloma (MM), but the authors of a new review article say much more work is needed.

MRD, Biomarkers in Multiple Myeloma

August 15th 2020, 9:39pm


Clinical updates for August 2020 featured in Evidence-Based Oncology.

MRD? We’re Aware of It, Say Oncologists, But We Don’t Use It for Decisions

August 14th 2020, 4:00am


Most oncologists in a recent survey said they lack the knowledge and data to use measurable, or minimal, residual disease (MRD) as a decision-making tool in the treatment of multiple myeloma.